Shaoyong Lu

Prof. Shaoyong Lu

Key Laboratory of Cell Differentiation and Apoptosis of Chinese Ministry of Education, Shanghai Jiao Tong University School of Medicine, Chongqing South Road 280, Shanghai 200025, China

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 April 2024 in Signal Transduction and Targeted Therapy
Verified
Journal Article
Open access
PDF file
MZMingyang Zhang
Mingyang Zhang
TCTing Chen
Ting Chen
XLXun Lu
Xun Lu
XLXiaobing Lan
Xiaobing Lan
ZCZiqiang Chen
Ziqiang Chen
SLShaoyong Lu
Shaoyong Lu
G protein-coupled receptors (GPCRs), the largest family of human membrane proteins and an important class of drug targets, play a role in maintaining numerous physiological processes. Agonist or antagonist, orthosteric effects or allosteric effects, and biased signaling or balanced signaling, characterize the complexity of GPCR dynamic features. In this study, we first review the structural advancements, activation mechanisms, and functional diversity of GPCRs. We then focus on GPCR drug discovery by revealing the detailed drug-target interactions and the underlying mechanisms of orthosteric drugs approved by the US Food and Drug Administration in the past five years. Particularly, an up-to-date analysis is performed on available GPCR structures complexed with synthetic small-molecule allosteric modulators to elucidate key receptor-ligand interactions and allosteric mechanisms. Finally, we highlight how the widespread GPCR-druggable allosteric sites can guide structure- or mechanism-based drug design and propose prospects of designing bitopic ligands for the future therapeutic potential of targeting this receptor family.

5 August 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
SLShaoyong Lu
Shaoyong Lu
XHXinheng He
Xinheng He
ZYZhao Yang
Zhao Yang
ZCZongtao Chai
Zongtao Chai
SZShuhua Zhou
Shuhua Zhou
JZJian Zhang
Jian Zhang
G protein-coupled receptors (GPCRs) are the most common proteins targeted by approved drugs. A complete mechanistic elucidation of large-scale conformational transitions underlying the activation mechanisms of GPCRs is of critical importance for therapeutic drug development. Here, we apply a combined computational and experimental framework integrating extensive molecular dynamics simulations, Markov state models, site-directed mutagenesis, and conformational biosensors to investigate the conformational landscape of the angiotensin II (AngII) type 1 receptor (AT 1 receptor) — a prototypical class A GPCR—activation. Our findings suggest a synergistic transition mechanism for AT 1 receptor activation. A key intermediate state is identified in the activation pathway, which possesses a cryptic binding site within the intracellular region of the receptor. Mutation of this cryptic site prevents activation of the downstream G protein signaling and β-arrestin-mediated pathways by the endogenous AngII octapeptide agonist, suggesting an allosteric regulatory mechanism. Together, these findings provide a deeper understanding of AT 1 receptor activation at an atomic level and suggest avenues for the design of allosteric AT 1 receptor modulators with a broad range of applications in GPCR biology, biophysics, and medicinal chemistry.

4 May 2021 in Frontiers in Chemistry
Verified
Journal Article
Open access
PDF file
XWXuefei Wang
Xuefei Wang
DNDuan Ni
Duan Ni
YLYaqin Liu
Yaqin Liu
SLShaoyong Lu
Shaoyong Lu
Protein-protein interactions (PPIs) are well-established as a class of promising drug targets for their implications in a wide range of biological processes. However, drug development toward PPIs is inevitably hampered by their flat and wide interfaces, which generally lack suitable pockets for ligand binding, rendering most PPI systems “undruggable.” Here, we summarized drug design strategies for developing peptide-based PPI inhibitors. Importantly, several quintessential examples toward well-established PPI targets such as Bcl-2 family members, p53-MDM2, as well as APC-Asef are presented to illustrate the detailed schemes for peptide-based PPI inhibitor development and optimizations. This review supplies a comprehensive overview of recent progresses in drug discovery targeting PPIs through peptides or peptidomimetics, and will shed light on future therapeutic agent development toward the historically “intractable” PPI systems.

2 November 2020 in Chemical Science
Verified
Journal Article
Open access
PDF file
DNDuan Ni
Duan Ni
JWJiacheng Wei
Jiacheng Wei
XHXinheng He
Xinheng He
ARAshfaq Ur Rehman
Ashfaq Ur Rehman
XLXinyi Li
Xinyi Li
JZJian Zhang
Jian Zhang
Allostery, which is one of the most direct and efficient methods to fine-tune protein functions, has gained increasing recognition in drug discovery. However, there are several challenges associated with the identification of allosteric sites, which is the fundamental cornerstone of drug design. Previous studies on allosteric site predictions have focused on communication signals propagating from the allosteric sites to the orthosteric sites. However, recent biochemical studies have revealed that allosteric coupling is bidirectional and that orthosteric perturbations can modulate allosteric sites through reversed allosteric communication. Here, we proposed a new framework for the prediction of allosteric sites based on reversed allosteric communication using a combination of computational and experimental strategies (molecular dynamics simulations, Markov state models, and site-directed mutagenesis). The desirable performance of our approach was demonstrated by predicting the known allosteric site of the small molecule MDL-801 in nicotinamide dinucleotide (NAD+)-dependent protein lysine deacetylase sirtuin 6 (Sirt6). A potential novel cryptic allosteric site located around the L116, R119, and S120 residues within the dynamic ensemble of Sirt6 was identified. The allosteric effect of the predicted site was further quantified and validated using both computational and experimental approaches. This study proposed a state-of-the-art computational pipeline for detecting allosteric sites based on reversed allosteric communication. This method enabled the identification of a previously uncharacterized potential cryptic allosteric site on Sirt6, which provides a starting point for allosteric drug design that can aid the identification of candidate pockets in other therapeutic targets.


1 January 2020 in Drug Discovery Today
Verified
Journal Article
Closed access
SLShaoyong Lu
Shaoyong Lu
YQYuran Qiu
Yuran Qiu
DNDuan Ni
Duan Ni
XHXinheng He
Xinheng He
JPJun Pu
Jun Pu
JZJian Zhang
Jian Zhang